Followed 117 TimesTop Followed Top-Rated StocksTop-Rated Most-Upgraded StocksMost-Upgraded

NYSE:LLY

Eli Lilly and Company (LLY) Price Target & Analyst Ratings

$550.54

+0.41 (+0.07%)

(As of 09/22/2023 ET)

Compare

Today's Range: $547.63
▼
$555.49
50-Day Range: $447.14
▼
$599.54
52-Week Range: $304.88
▼
$601.84

Volume: 2.35 million shs
Average Volume: 2.76 million shs
Market Capitalization: $522.62 billion

P/E Ratio: 76.57
Dividend Yield: 0.82%
Price Target: $532.78

Eli Lilly and Company Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 21 Analyst Ratings

Consensus Analyst Price Target

$532.78
-3.23% Downside

High Prediction	$640.00
Average Prediction	$532.78
Low Prediction	$278.00

Type	Current 9/24/22 to 9/24/23	1 Month Ago 8/25/22 to 8/25/23	3 Months Ago 6/26/22 to 6/26/23	1 Year Ago 9/24/21 to 9/24/22
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	19 Buy rating(s)	18 Buy rating(s)	12 Buy rating(s)	13 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	2 Hold rating(s)	3 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$532.78	$520.48	$431.00	$332.19
Predicted Upside	-3.23% Downside	12.36% Upside	14.00% Upside	16.95% Upside

Get Eli Lilly and Company Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for LLY and its competitors with MarketBeat's FREE daily newsletter.

LLY Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

LLY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Eli Lilly and Company Stock vs. The Competition

Type	Eli Lilly and Company	Medical Companies	S&P 500
Consensus Rating Score	2.86	2.66	2.49
Consensus Rating	Moderate Buy	Moderate Buy	Hold
Predicted Upside	-3.23% Downside	1,391.31% Upside	629.68% Upside
News Sentiment Rating	Neutral News	Positive News	Positive News

Historical Target Prices and Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Action	Rating	Price Target	Upside/Downside on Report Date
9/5/2023	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$630.00	+12.56%
9/5/2023	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$470.00 ➝ $620.00	+10.67%
9/5/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$617.00 ➝ $640.00	+14.88%
8/9/2023	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Neutral ➝ Neutral	$385.00 ➝ $470.00	-10.69%
8/9/2023	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$565.00 ➝ $633.00	+20.82%
8/9/2023	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$525.00 ➝ $600.00	+14.52%
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter.
8/9/2023	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$500.00 ➝ $590.00	+13.26%
8/9/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$510.00 ➝ $600.00	+15.03%
8/9/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$490.00 ➝ $580.00	+11.20%
8/9/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target		$500.00 ➝ $600.00	+15.03%
8/8/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$408.00 ➝ $615.00	+17.91%
8/8/2023	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$490.00 ➝ $580.00	+11.20%
8/8/2023	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$500.00 ➝ $615.00	+19.49%
7/26/2023	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy	$360.00 ➝ $525.00	+16.63%
7/14/2023	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$560.00	+28.82%
6/27/2023	22nd Century Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Maintains
6/20/2023	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target		$375.00 ➝ $500.00	+10.15%
5/24/2023	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy	$447.00 ➝ $498.00	+16.96%
5/1/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target		$410.00 ➝ $458.00	+15.70%
4/28/2023	3M Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Maintains
4/11/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy	$395.00 ➝ $392.00	+6.81%
2/15/2023	Societe Generale Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Hold ➝ Sell	$278.00	-18.41%
12/16/2022	SVB Leerink Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform	$384.00 ➝ $410.00	+13.93%
12/5/2022	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform	$390.00 ➝ $430.00	+14.74%

(Data available from 9/24/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

LLY Price Target - Frequently Asked Questions

What is Eli Lilly and Company's consensus rating and price target?: According to the issued ratings of 21 analysts in the last year, the consensus rating for Eli Lilly and Company stock is Moderate Buy based on the current 1 sell rating, 1 hold rating and 19 buy ratings for LLY. The average twelve-month price prediction for Eli Lilly and Company is $532.78 with a high price target of $640.00 and a low price target of $278.00. Learn more on LLY's analyst rating history.
Do Wall Street analysts like Eli Lilly and Company more than its competitors?: Analysts like Eli Lilly and Company more than other Medical companies. The consensus rating score for Eli Lilly and Company is 2.86 while the average consensus rating score for medical companies is 2.66. Learn more on how LLY compares to other companies.
Is Eli Lilly and Company being upgraded by Wall Street analysts?: Over the previous 90 days, Eli Lilly and Company's stock had 1 upgrade by analysts.

Does Eli Lilly and Company's stock price have much upside?: According to analysts, Eli Lilly and Company's stock has a predicted upside of 12.80% based on their 12-month price targets.
What analysts cover Eli Lilly and Company?: Eli Lilly and Company has been rated by 22nd Century Group, Argus, Bank of America, Barclays, BMO Capital Markets, Cantor Fitzgerald, Citigroup, Credit Suisse Group, HSBC, Jefferies Financial Group, JPMorgan Chase & Co., Morgan Stanley, Royal Bank of Canada, The Goldman Sachs Group, Truist Financial, and Wells Fargo & Company in the past 90 days.

Stock Ratings Reports and Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

This page (NYSE:LLY) was last updated on 9/24/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial